Role of Low-Affinity Nerve Growth Factor Receptor Inhibitory Antibody in Reducing Pain Behavior and Calcitonin Gene-Related Peptide Expression in a Rat Model of Wrist Joint Inflammatory Pain

Iwakura, Nahoko; Ohtori, Seiji; Orita, Sumihisa; Yamashita, Masaomi; Takahashi, Kazuhisa; Kuniyoshi, Kazuki

doi:10.1016/j.jhsa.2009.10.030

Cited by 25 publications

(20 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This anti-NGF inhibition of weight loss confirms and extends what was previously reported in a rat model of Freund's induced osteoarthritis (39), and a mouse model of head/neck cancer (40), where anti-NGF markedly reduced weight loss. Currently, we do not know whether this inhibition of weight loss in the present study was due to blockade of a circulating anti-cachexia effect or reduction in pain/disease progression which allows the animal to maintain an appetite.…”

Section: Discussionsupporting

confidence: 90%

“…Additionally, as suggested in previous studies in animal models of osteoarthritis (39) and head/neck cancer (40), early blockade of NGF also reduced weight loss in animals with bone cancer. In terms of the extent and time course of pain relief, blockade of NGF reduced bone cancer pain by 40-70% depending on the pain measure being assessed, and this analgesic effect was maintained even in animals with late stage disease.…”

Section: Discussionsupporting

confidence: 68%

See 1 more Smart Citation

NGF Blockade at Early Times during Bone Cancer Development Attenuates Bone Destruction and Increases Limb Use

et al. 2014

View full text Add to dashboard Cite

Studies in animals and humans show that blockade of nerve growth factor (NGF) attenuates both malignant and non-malignant skeletal pain. While reduction of pain is important, a largely unanswered question is what other benefits NGF blockade might confer in bone cancer patients. Using a mouse graft model of bone sarcoma, we demonstrate that early treatment with an NGF antibody reduced tumor-induced bone destruction, delayed time to bone fracture, and increased the use of the tumor-bearing limb. Consistent with animal studies in osteoarthritis and head and neck cancer, early blockade of NGF reduced weight loss in mice with bone sarcoma. In terms of the extent and time course of pain relief, NGF blockade also reduced pain 40-70% depending on the metric assessed. Importantly, this analgesic effect was maintained even in animals with late stage disease. Our results suggest that NGF blockade immediately upon detection of tumor metastasis to bone may help preserve the integrity and use, delay the time to tumor-induced bone fracture, and maintain body weight.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionsupporting

confidence: 68%

NGF Blockade at Early Times during Bone Cancer Development Attenuates Bone Destruction and Increases Limb Use

et al. 2014

View full text Add to dashboard Cite

show abstract

“…However, in our previous study, we demonstrated that in the rat CFA-induced pain model there were no changes in the intake of food pellets, quantity of water drunk, weight of feces, or change in body weight compared with the sham-surgery group, and there were no signs of major infection such as septic bronchitis or arthritis. 34 In conclusion, our results suggest that p75NTR contributes to neuropathic pain associated with BPA, and that inhibition of p75NTR reduces neuropathic pain and suppresses glial cells. p75NTR might represent a valid therapeutic target for the clinical treatment of pain after brachial plexus injury.…”

Section: Discussionsupporting

confidence: 54%

The Effect of Anti-NGF Receptor (p75 Neurotrophin Receptor) Antibodies on Nociceptive Behavior and Activation of Spinal Microglia in the Rat Brachial Plexus Avulsion Model

Matsuura

Iwakura²,

Ohtori³

et al. 2013

Spine

Self Cite

View full text Add to dashboard Cite

show abstract

“…In another rat Freund's adjuvant wrist joint study, an antibody to p75 neurotrophin receptor (p75NTR) was injected directly into the joint after the onset of inflammation. Direct p75NTR inhibitory antibody application decreased calcitonin gene-related protein and p75NTR expression after wrist inflammation (p < 0.01) [35].…”

Section: • Calcitonin Gene-related Proteinmentioning

confidence: 93%

A Background for the Management of Osteoarthritic Knee Pain

Nelson

2014

Pain Manag.

View full text Add to dashboard Cite

Knee osteoarthritis (KOA) is the most common degenerative arthritis and is treated by a wide range of practitioners. Treatment planning requires knowledge of the knee joint components and the influence of systemic and environmental factors. The treatment of KOA has changed little in 50 years. We are entering a new stage where KOA is now being viewed as an organ in failure. Neurotransmission of pain is both peripheral and central. Medical treatment can influence both pathways. Current guidelines for treatment have more rigid criteria based on the literature. In the future, the use of genetic-based biomarkers, clinical patterns of response and imaging characteristics will likely create subgroups of individuals who could benefit from improved designer therapies.

show abstract

Role of Low-Affinity Nerve Growth Factor Receptor Inhibitory Antibody in Reducing Pain Behavior and Calcitonin Gene-Related Peptide Expression in a Rat Model of Wrist Joint Inflammatory Pain

Cited by 25 publications

References 28 publications

NGF Blockade at Early Times during Bone Cancer Development Attenuates Bone Destruction and Increases Limb Use

NGF Blockade at Early Times during Bone Cancer Development Attenuates Bone Destruction and Increases Limb Use

The Effect of Anti-NGF Receptor (p75 Neurotrophin Receptor) Antibodies on Nociceptive Behavior and Activation of Spinal Microglia in the Rat Brachial Plexus Avulsion Model

A Background for the Management of Osteoarthritic Knee Pain

Contact Info

Product

Resources

About